Austin, Texas, United States, November 19, 2026
Genprex, Inc. has announced new research findings identifying TROP2 expression as a potential predictive biomarker for its investigational gene therapy candidate, REQORSA® (quaratusugene ozeplasmid), in the treatment of non-small cell lung cancer (NSCLC). The findings were presented at the 2026 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, held from November 18 to 20 in Barcelona, Spain. The research suggests that differences in TROP2 protein expression may help explain why some lung cancer models respond differently to TUSC2 gene therapy. In particular, low TROP2 expression was associated with primary resistance to REQORSA across several preclinical models. The findings could support the development of a more targeted patient-selection strategy as Genprex continues investigating REQORSA in lung cancer. The research also explored whether changing TROP2 expression could influence the sensitivity of cancer cells to the gene therapy, opening another area for further investigation.
TROP2 Expression May Help Predict REQORSA Response
The research, presented under the title TROP2 Predicts Response to TUSC2 Gene Therapy and Its Modulation Sensitizes Non-Small Cell Lung Cancer to Treatment, examined the relationship between TROP2 protein expression and response to TUSC2 gene delivery. Investigators evaluated multiple NSCLC cell lines and patient-derived organoid models to understand the biological factors associated with treatment resistance. Approximately 50% of the 10 NSCLC cell lines and 50% of the 12 patient-derived organoid models assessed demonstrated primary resistance to TUSC2 gene delivery. Protein-expression analyses consistently identified low TROP2 expression as a potential marker associated with this resistance. Importantly, the research also included analysis of pretreatment tumour biopsies from patients enrolled in a clinical trial evaluating TUSC2 gene therapy. These patient samples provided supporting clinical evidence for an association between TROP2 expression and treatment response. Although the findings are encouraging, the company emphasised that further research and prospective clinical evaluation will be required to establish whether TROP2 can reliably predict which patients will benefit from REQORSA. A validated biomarker could eventually help researchers refine clinical trial enrolment and investigate more personalised treatment approaches for people with lung cancer.
Experimental TROP2 Modulation Influences Treatment Sensitivity
In addition to evaluating TROP2 as a potential biomarker, researchers investigated whether altering its expression could change how NSCLC cells respond to TUSC2 gene therapy. In TROP2-low cancer cell models, including H460 and H1299 cells, introducing TROP2 significantly increased TUSC2-induced apoptosis, bringing the response to levels similar to those observed in cells that naturally express higher levels of TROP2. The investigators also reported that reducing or eliminating TROP2 expression in TROP2-high cell models, including H358 and H322 cells, using short hairpin RNA (shRNA) and CRISPR/Cas9 gene-editing techniques, significantly increased sensitivity to TUSC2 gene therapy. These experimental observations suggest that the relationship between TROP2 expression and treatment response may involve context-dependent cellular mechanisms. Further investigation will be necessary to understand how TROP2-associated signalling influences the therapeutic activity of REQORSA and whether manipulating this pathway could improve treatment outcomes. The research therefore provides two important directions for future studies: evaluating TROP2 as a tool for predicting treatment response and exploring its potential role in modifying cancer-cell sensitivity to gene therapy.
REQORSA Uses TUSC2 Gene Delivery for Lung Cancer
REQORSA (quaratusugene ozeplasmid) is Genprex’s investigational gene therapy designed to deliver a functional copy of the TUSC2 tumour suppressor gene into cancer cells. TUSC2 protein expression is downregulated or absent in more than 80% of NSCLC cases and nearly all small cell lung cancers, according to the company. REQORSA uses Genprex’s proprietary ONCOPREX® Delivery System, which packages a TUSC2-containing plasmid within non-viral, lipid-based nanoparticles. Administered intravenously, the treatment is designed to deliver the functional gene to cancer cells and restore tumour-suppressive activity. Previous research has indicated that TUSC2 activity can affect multiple cancer-related pathways, including MAPK and mTOR signalling, while promoting cell-cycle arrest, apoptosis and antitumour immune responses. Genprex is evaluating REQORSA in its ACCLAIM-1 and ACCLAIM-3 clinical programmes for NSCLC and small cell lung cancer, respectively. The company has also reported that the US Food and Drug Administration granted Fast Track Designation to both lung cancer programmes and Orphan Drug Designation to its small cell lung cancer programme. The newly presented TROP2 findings add to the candidate’s research programme by highlighting a possible biomarker-based approach to treatment development. However, REQORSA remains investigational, and the predictive value of TROP2 has not yet been established for routine clinical use. Further studies will be needed to confirm these findings and determine their potential role in future lung cancer treatment strategies.
Source: Genprex press release



